Jazz Pharmaceuticals plc Research and Development Expense
Jazz Pharmaceuticals plc (JAZZ) reported Research and Development Expense of $299.73 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2020-02-25
- Jazz Pharmaceuticals plc research and development expense for the quarter ending 2019-12-31 was $97.38M, a 71.88% increase year-over-year.
- Jazz Pharmaceuticals plc research and development expense for the quarter ending 2019-09-30 was $79.86M, a 56.09% increase year-over-year.
- Jazz Pharmaceuticals plc research and development expense for the quarter ending 2019-06-30 was $62.38M, a 11.14% increase year-over-year.
- Jazz Pharmaceuticals plc research and development expense for the quarter ending 2019-03-31 was $60.10M, a 4.09% decline year-over-year.
- Jazz Pharmaceuticals plc research and development expense for fiscal 2019 was $299.73M, a 32.26% increase from fiscal 2018.
- Jazz Pharmaceuticals plc research and development expense for fiscal 2018 was $226.62M, a 14.20% increase from fiscal 2017.
- Jazz Pharmaceuticals plc research and development expense for fiscal 2017 was $198.44M, a 22.27% increase from fiscal 2016.
- Jazz Pharmaceuticals plc research and development expense for fiscal 2016 was $162.30M, a 20.00% increase from fiscal 2015.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | $97.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $177.24M derived: sum of 2 quarters · filed 2020-02-25 | $239.62M derived: sum of 3 quarters · filed 2020-02-25 | $299.73M 10-K · filed 2020-02-25 | ||||
| 2019-09-30 | $79.86M 10-Q · filed 2019-11-05 | $142.24M derived: sum of 2 quarters · filed 2019-11-05 | $202.34M 10-Q · filed 2019-11-05 | $259.00M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2019-06-30 | $62.38M 10-Q · filed 2019-08-06 | $122.49M 10-Q · filed 2019-08-06 | $179.15M derived: sum of 3 quarters · filed 2020-02-25 | $230.31M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2019-03-31 | $60.10M 10-Q · filed 2019-05-07 | $116.76M derived: sum of 2 quarters · filed 2020-02-25 | $167.92M derived: sum of 3 quarters · filed 2020-02-25 | $224.05M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-12-31 | $56.66M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $107.82M derived: sum of 2 quarters · filed 2020-02-25 | $163.95M derived: sum of 3 quarters · filed 2020-02-25 | $226.62M 10-K · filed 2020-02-25 | ||||
| 2018-09-30 | $51.16M 10-Q · filed 2019-11-05 | $107.29M derived: sum of 2 quarters · filed 2019-11-05 | $169.96M 10-Q · filed 2019-11-05 | $235.95M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-06-30 | $56.13M 10-Q · filed 2019-08-06 | $118.80M 10-Q · filed 2019-08-06 | $184.79M derived: sum of 3 quarters · filed 2020-02-25 | $232.16M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-03-31 | $62.67M 10-Q · filed 2019-05-07 | $128.66M derived: sum of 2 quarters · filed 2020-02-25 | $176.02M derived: sum of 3 quarters · filed 2020-02-25 | $216.18M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2017-12-31 | $66.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $113.36M derived: sum of 2 quarters · filed 2020-02-25 | $153.51M derived: sum of 3 quarters · filed 2020-02-25 | $198.44M 10-K · filed 2020-02-25 | ||||
| 2017-09-30 | $47.36M 10-Q · filed 2018-11-06 | $87.52M derived: sum of 2 quarters · filed 2018-11-06 | $132.45M 10-Q · filed 2018-11-06 | $176.60M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-06-30 | $40.16M 10-Q · filed 2018-08-07 | $85.08M 10-Q · filed 2018-08-07 | $129.24M derived: sum of 3 quarters · filed 2019-02-26 | $177.04M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-03-31 | $44.93M 10-Q · filed 2018-05-08 | $89.09M derived: sum of 2 quarters · filed 2019-02-26 | $136.88M derived: sum of 3 quarters · filed 2019-02-26 | $175.97M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2016-12-31 | $44.16M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $91.95M derived: sum of 2 quarters · filed 2019-02-26 | $131.04M derived: sum of 3 quarters · filed 2019-02-26 | $162.30M 10-K · filed 2019-02-26 | ||||
| 2016-09-30 | $47.80M 10-Q · filed 2017-11-07 | $86.89M derived: sum of 2 quarters · filed 2017-11-07 | $118.14M 10-Q · filed 2017-11-07 | $147.59M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-06-30 | $39.09M 10-Q · filed 2017-08-08 | $70.34M 10-Q · filed 2017-08-08 | $99.80M derived: sum of 3 quarters · filed 2018-02-27 | $150.58M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-03-31 | $31.25M 10-Q · filed 2017-05-09 | $60.71M derived: sum of 2 quarters · filed 2018-02-27 | $111.49M derived: sum of 3 quarters · filed 2018-02-27 | $139.32M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2015-12-31 | $29.45M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $80.24M derived: sum of 2 quarters · filed 2018-02-27 | $108.07M derived: sum of 3 quarters · filed 2018-02-27 | $135.25M 10-K · filed 2018-02-27 | ||||
| 2015-09-30 | $50.78M 10-Q · filed 2016-11-08 | $78.62M derived: sum of 2 quarters · filed 2016-11-08 | $105.80M 10-Q · filed 2016-11-08 | $130.36M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-06-30 | $27.83M 10-Q · filed 2016-08-09 | $55.01M 10-Q · filed 2016-08-09 | $79.57M derived: sum of 3 quarters · filed 2017-02-28 | $102.00M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-03-31 | $27.18M 10-Q · filed 2016-05-10 | $51.74M derived: sum of 2 quarters · filed 2017-02-28 | $74.16M derived: sum of 3 quarters · filed 2017-02-28 | $94.25M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2014-12-31 | $24.56M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $46.98M derived: sum of 2 quarters · filed 2017-02-28 | $67.07M derived: sum of 3 quarters · filed 2017-02-28 | $85.18M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $22.42M 10-Q · filed 2015-11-09 | $42.51M derived: sum of 2 quarters · filed 2015-11-09 | $60.62M 10-Q · filed 2015-11-09 | $74.43M derived: sum of 4 quarters · filed 2016-02-23 | ||||
| 2014-06-30 | $20.09M 10-Q · filed 2015-08-05 | $38.20M 10-Q · filed 2015-08-05 | $52.01M derived: sum of 3 quarters · filed 2016-02-23 | $63.83M derived: sum of 4 quarters · filed 2016-02-23 | ||||
| 2014-03-31 | $18.11M 10-Q · filed 2015-05-07 | $31.92M derived: sum of 2 quarters · filed 2016-02-23 | $43.74M derived: sum of 3 quarters · filed 2016-02-23 | $52.99M derived: sum of 4 quarters · filed 2016-02-23 | ||||
| 2013-12-31 | $13.81M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $25.64M derived: sum of 2 quarters · filed 2016-02-23 | $34.88M derived: sum of 3 quarters · filed 2016-02-23 | $41.63M 10-K · filed 2016-02-23 | $46.62M 10-K · filed 2014-02-25 | |||
| 2013-09-30 | $11.83M 10-Q · filed 2014-11-04 | $12.81M 10-Q · filed 2013-11-05 | $21.08M derived: sum of 2 quarters · filed 2014-11-04 | $27.82M 10-Q · filed 2014-11-04 | $32.81M 10-Q · filed 2013-11-05 | $35.10M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2013-06-30 | $9.25M 10-Q · filed 2014-08-05 | $16.00M 10-Q · filed 2014-08-05 | $20.00M 10-Q · filed 2013-08-06 | $23.27M derived: sum of 3 quarters · filed 2015-02-24 | $30.19M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2013-03-31 | $6.75M 10-Q · filed 2014-05-08 | $10.75M 10-Q · filed 2013-05-07 | $14.02M derived: sum of 2 quarters · filed 2015-02-24 | $20.94M derived: sum of 3 quarters · filed 2015-02-24 | $23.27M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2012-12-31 | $7.28M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $14.20M derived: sum of 2 quarters · filed 2015-02-24 | $16.52M derived: sum of 3 quarters · filed 2015-02-24 | $20.48M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $6.92M 10-Q · filed 2013-11-05 | $9.24M derived: sum of 2 quarters · filed 2013-11-05 | $13.20M 10-Q · filed 2013-11-05 | $16.96M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $2.32M 10-Q · filed 2013-08-06 | $6.28M 10-Q · filed 2013-08-06 | $10.04M derived: sum of 3 quarters · filed 2014-02-25 | $13.32M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $3.96M 10-Q · filed 2013-05-07 | $7.72M derived: sum of 2 quarters · filed 2014-02-25 | $11.00M derived: sum of 3 quarters · filed 2014-02-25 | $14.38M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $3.76M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $7.04M derived: sum of 2 quarters · filed 2014-02-25 | $10.43M derived: sum of 3 quarters · filed 2014-02-25 | $14.12M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $3.28M 10-Q · filed 2012-11-09 | $6.66M derived: sum of 2 quarters · filed 2012-11-09 | $10.36M 10-Q · filed 2012-11-09 | $14.47M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $3.38M 10-Q · filed 2012-08-07 | $7.08M 10-Q · filed 2012-08-07 | $11.20M derived: sum of 3 quarters · filed 2013-02-26 | $18.51M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $3.69M 10-Q · filed 2012-05-08 | $7.81M derived: sum of 2 quarters · filed 2013-02-26 | $15.13M derived: sum of 3 quarters · filed 2013-02-26 | $23.09M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $11.44M derived: sum of 2 quarters · filed 2013-02-26 | $19.40M derived: sum of 3 quarters · filed 2013-02-26 | $25.61M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $7.32M 10-Q · filed 2011-11-08 | $15.28M derived: sum of 2 quarters · filed 2011-11-08 | $21.49M 10-Q · filed 2011-11-08 | |||||
| 2010-06-30 | $7.96M 10-Q · filed 2011-08-03 | $14.18M 10-Q · filed 2011-08-03 | ||||||
| 2009-12-31 | $36.56M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |